Subtopic Deep Dive

Xanthohumol Metabolism Pharmacokinetics
Research Guide

What is Xanthohumol Metabolism Pharmacokinetics?

Xanthohumol metabolism pharmacokinetics studies the absorption, distribution, metabolism, and excretion of xanthohumol, a prenylated flavonoid from hops, including its conversion to isoxanthohumol and conjugates in humans and animal models.

Research identifies phase I metabolism via liver microsomes converting xanthohumol to isoxanthohumol and phase II glucuronidation/sulfation. Human studies report low oral bioavailability with rapid conjugation (Legette et al., 2013, 128 citations; Legette et al., 2011, 117 citations). Rat models show dose-dependent pharmacokinetics after oral and IV dosing (Legette et al., 2011). Over 10 key papers span 2006-2019.

Curated Papers

Key Challenges

Why It Matters

Understanding xanthohumol pharmacokinetics enables optimization of dosing for antihyperglycemic effects in type 2 diabetes prevention (Legette et al., 2013). It predicts variability in menopause symptom relief from hop extracts due to prenylflavonoid metabolism (van Breemen et al., 2014; Dietz et al., 2016). Gut microbiota influence on isoxanthohumol formation affects bioavailability for anti-inflammatory applications (Bolca et al., 2007). These insights support therapeutic development of hop-derived supplements.

Key Research Challenges

Low Oral Bioavailability

Xanthohumol exhibits poor absorption with rapid phase II conjugation, limiting systemic exposure (Legette et al., 2013). Strategies to enhance bioavailability remain underdeveloped. Inter-species differences complicate translation from rat to human PK (Legette et al., 2011).

Microbiota-Dependent Metabolism

Gut bacteria convert xanthohumol to bioactive isoxanthohumol, causing donor variability (Bolca et al., 2007). Standardizing microbiota effects in PK models is challenging. Dietary interventions show inconsistent producer phenotypes (Bolca et al., 2007).

Metabolite Quantification

Detecting low-concentration conjugates requires sensitive LC-MS methods (van Breemen et al., 2014). Validating metabolites across studies is inconsistent. Human trial data on long-term accumulation is limited (Legette et al., 2013).

Essential Papers

The Cancer Prevention, Anti-Inflammatory and Anti-Oxidation of Bioactive Phytochemicals Targeting the TLR4 Signaling Pathway

Chung‐Yi Chen, Chiu‐Li Kao, Chi-Ming Liu · 2018 · International Journal of Molecular Sciences · 336 citations

Toll-like receptors (TLRs) are a well-known family of pattern recognition receptors that play an important role in a host immune system. TLR triggering leads to the induction of pro-inflammatory cy...

Anticancer Activity and Mechanism of Xanthohumol: A Prenylated Flavonoid From Hops (Humulus lupulus L.)

Chuanhao Jiang, Taoli Sun, Daxiong Xiang et al. · 2018 · Frontiers in Pharmacology · 251 citations

It has been observed that many phytochemicals, frequently present in foods or beverages, show potent chemopreventive or therapeutic properties that selectively affect cancer cells. Numerous studies...

Oxidative stress, hormones, and effects of natural antioxidants on intestinal inflammation in inflammatory bowel disease

Dipak Kumar Sahoo, Romy M. Heilmann, Biswaranjan Paital et al. · 2023 · Frontiers in Endocrinology · 250 citations

Inflammatory bowel disease (IBD) is a chronic, relapsing gastrointestinal (GI) disorder characterized by intestinal inflammation. The etiology of IBD is multifactorial and results from a complex in...

Pharmacological Profile of Xanthohumol, a Prenylated Flavonoid from Hops (Humulus lupulus)

Ming Liu, Poul Erik Hansen, Genzhu Wang et al. · 2015 · Molecules · 238 citations

The female inflorescences of hops (Humulus lupulus L.), a well-known bittering agent used in the brewing industry, have long been used in traditional medicines. Xanthohumol (XN) is one of the bioac...

Botanicals and Their Bioactive Phytochemicals for Women’s Health

Birgit M. Dietz, Atieh Hajirahimkhan, Tareisha L. Dunlap et al. · 2016 · Pharmacological Reviews · 226 citations

Hop Compounds: Extraction Techniques, Chemical Analyses, Antioxidative, Antimicrobial, and Anticarcinogenic Effects

Maša Knez Hrnčič, Eva Španinger, Iztok Jože Košir et al. · 2019 · Nutrients · 186 citations

Hop plants comprise a variety of natural compounds greatly differing in their structure and properties. A wide range of methods have been developed for their isolation and chemical analysis, as wel...

Human pharmacokinetics of xanthohumol, an antihyperglycemic flavonoid from hops

LeeCole Legette, Chanida Karnpracha, Ralph L. Reed et al. · 2013 · Molecular Nutrition & Food Research · 128 citations

Scope Xanthohumol ( XN ) is a bioactive prenylflavonoid from hops. A single‐dose pharmacokinetic ( PK ) study was conducted in men ( n = 24) and women ( n = 24) to determine dose–concentration rela...

Reading Guide

Foundational Papers

Start with Legette et al. (2013, 128 citations) for human single-dose PK and Legette et al. (2011, 117 citations) for rat oral/IV parameters to grasp core ADME profiles.

Recent Advances

Study van Breemen et al. (2014, 108 citations) for women-specific hop phenol PK and Liu et al. (2015, 238 citations) for pharmacological overview including metabolism.

Core Methods

LC-MS for metabolite detection (van Breemen et al., 2014); non-compartmental analysis for AUC/Cmax (Legette et al., 2013); microbiota assays for bioactivation (Bolca et al., 2007).

How PapersFlow Helps You Research Xanthohumol Metabolism Pharmacokinetics

Discover & Search

Research Agent uses searchPapers and exaSearch to find all xanthohumol PK studies, then citationGraph on Legette et al. (2013) reveals 128 citing papers including van Breemen et al. (2014), while findSimilarPapers identifies rat model extensions like Legette et al. (2011).

Analyze & Verify

Analysis Agent applies readPaperContent to extract PK parameters from Legette et al. (2013), then runPythonAnalysis with pandas to plot dose-concentration curves and verifyResponse via CoVe against raw data, achieving GRADE high evidence for human bioavailability claims.

Synthesize & Write

Synthesis Agent detects gaps in microbiota-PK links via contradiction flagging across Bolca et al. (2007) and Legette studies, then Writing Agent uses latexEditText, latexSyncCitations, and latexCompile to generate a PK pathway figure with exportMermaid.

Use Cases

"Plot xanthohumol plasma concentration-time curves from human trials"

Research Agent → searchPapers('xanthohumol human pharmacokinetics') → Analysis Agent → readPaperContent(Legette 2013) → runPythonAnalysis(pandas plot AUC/Cmax) → matplotlib graph of dose-response.

"Write LaTeX review on xanthohumol metabolism pathways"

Synthesis Agent → gap detection → Writing Agent → latexEditText(draft pathways) → latexSyncCitations(Legette 2011, van Breemen 2014) → latexCompile → PDF with cited PK diagrams.

"Find code for simulating xanthohumol glucuronidation kinetics"

Research Agent → paperExtractUrls('xanthohumol PK modeling') → Code Discovery → paperFindGithubRepo → githubRepoInspect → PK simulation script in Python sandbox.

Automated Workflows

Deep Research workflow scans 50+ papers via citationGraph from Legette et al. (2013), producing structured PK summary with GRADE scores. DeepScan applies 7-step CoVe to verify microbiota claims in Bolca et al. (2007) against human data. Theorizer generates hypotheses on formulation strategies to boost bioavailability from metabolism gaps.

Try Doxa for Xanthohumol Metabolism Pharmacokinetics Research

Frequently Asked Questions

What defines xanthohumol metabolism pharmacokinetics?

It covers ADME processes of xanthohumol from hops, focusing on phase I isomerization to isoxanthohumol and phase II conjugation in liver and gut (Legette et al., 2013).

What are key methods in xanthohumol PK studies?

LC-MS quantifies metabolites in plasma/urine after oral/IV dosing; human trials use single-dose designs (Legette et al., 2013); rat studies compare routes (Legette et al., 2011).

What are foundational papers?

Legette et al. (2013, 128 citations) on human PK; Legette et al. (2011, 117 citations) on rat PK; van Breemen et al. (2014, 108 citations) on hop phenols in women.

What open problems exist?

Enhancing bioavailability beyond low 1-2% absorption; standardizing microbiota conversion variability; long-term human accumulation data (Bolca et al., 2007; Legette et al., 2013).